Foreign exchange swings cost North American corporates $18.66 billion in revenue in the fourth quarter, according to a report by currency risk management consulting firm FiREapps.
AstraZeneca moved to strengthen its core oncology business on Tuesday with three deals designed to expand the British drugmaker's reach in treating tumors.
U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.
After lackluster activity in the past years, pharmaceutical firms have gotten back to producing new drugs but they encounter challenges in selling them, according to a report on The Wall Street Journal.
An announcement made last Thursday of a realignment in priority drug research projects prompted Citi analyst to advise shareholders of a possible interest divestment in diabetes drug joint venture between Bristol-Myers Squibb and AstraZeneca.
Robert Ramnarine, former Bristol-Myers executive pleaded guilty to the insider trading charges filed against him.